Cargando…

Chemoselective Covalent Modification of K-Ras(G12R) with a Small Molecule Electrophile

[Image: see text] KRAS mutations are one of the most common oncogenic drivers in human cancer. While small molecule inhibitors for the G12C mutant have been successfully developed, allele-specific inhibition for other KRAS hotspot mutants remains challenging. Here we report the discovery of covalent...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ziyang, Morstein, Johannes, Ecker, Andrew K., Guiley, Keelan Z., Shokat, Kevan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9460778/
https://www.ncbi.nlm.nih.gov/pubmed/36001446
http://dx.doi.org/10.1021/jacs.2c05377
Descripción
Sumario:[Image: see text] KRAS mutations are one of the most common oncogenic drivers in human cancer. While small molecule inhibitors for the G12C mutant have been successfully developed, allele-specific inhibition for other KRAS hotspot mutants remains challenging. Here we report the discovery of covalent chemical ligands for the common oncogenic mutant K-Ras(G12R). These ligands bind in the Switch II pocket and irreversibly react with the mutant arginine residue. An X-ray crystal structure reveals an imidazolium condensation product formed between the α,β-diketoamide ligand and the ε- and η-nitrogens of arginine 12. Our results show that arginine residues can be selectively targeted with small molecule electrophiles despite their weak nucleophilicity and provide the basis for the development of mutant-specific therapies for K-Ras(G12R)-driven cancer.